XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Net sales $ 676,844 $ 700,062
Cost of goods sold 314,427 297,427
Gross profit 362,417 402,635
Selling, general and administrative expense 225,553 196,692
Research and Development Expense 74,951 59,535
Segment profit (loss) 61,913 146,408
Interest expense 12,337 4,048
Foreign exchange (gains) losses, net (2,347) (2,128)
Marketable Securities, Unrealized (Gain) Loss 17,525 4,545,117
Other Nonoperating Income (Expense) 50,431 32,597
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 84,829 (4,368,032)
(Provision) benefit for income taxes (15,867) 1,000,685
Net income attributable to Bio-Rad $ 68,962 $ (3,367,347)
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad $ 2.33 $ (112.50)
Weighted average common shares - basic 29,596 29,933
Diluted earnings per share:    
Net income per share diluted attributable to Bio-Rad $ 2.32 $ (112.50)
Weighted average common shares - diluted 29,747 29,933